Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function.

ABSTRACT:

Background

Little is known about the potential benefits or harms of statins on physical function among people with human immunodeficiency virus (PWH).

Methods

REPRIEVE was a double-blind randomized controlled trial evaluating pitavastatin for primary prevention of major adverse cardiovascular events in PWH. Time to complete 10 chair rises, 4-m gait speed, grip strength, and a modified short physical performance test were assessed annually for up to 5 years in the ancillary study PREPARE and analyzed using linear mixed models.

Findings

Of 602 PWH, 52% were randomized to pitavastatin and 48% to placebo. Median age was 51 years; 18% were female at birth; 2% transgender; and 40% Black, and 18% Hispanic. Median PREPARE follow-up was 4.7 (4.3-5.0) years. Muscle symptoms (gr

SUBMITTER: Erlandson KM 

PROVIDER: S-EPMC11848279 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature